Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Xeniopro GmbH is active in the Biotechnology & Pharmaceuticals technology area. The portfolio shows 1 pending office action at this time. This activity is handled by 1 distinct examiner working within 1 distinct art unit. The current prosecution profile is narrow, with all active matters focused on a lone examiner and art unit within the biotechnology sector. This narrow prosecution profile indicates that the company is currently managing a very specific set of claims through the patent office's review process.
PECKHAM, RICHARD GRANT is identified as the busiest examiner for the company. This examiner is responsible for 1 busiest examiner pending office action. Because this examiner oversees the company's full active workload, practitioners can focus their efforts on the specific requirements and tendencies of this individual. The company's success in obtaining patent protection is tied to the resolution of this single action, making the examiner's individual review process the most significant factor in current prosecution efforts. Because the entire active workload is handled by this single examiner, the company's legal team can focus all of its resources on meeting the specific technical standards of this individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17270646 | NOVEL AROMATIC MOLECULES | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17270646 | NOVEL AROMATIC MOLECULES | PECKHAM, RICHARD GRANT | 1600 | §102§103§112DP | Final Rejection | — | Pending | Feb 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial